Skip to main content

New insights from study of people age 90 and above

By Carousel Slider, Commentary, In the News
CBS: Six years after our initial report, Lesley Stahl visits surviving members of the 90+ Study and finds out what scientists have learned from following the study's participants. We're a nation living longer and longer. Over the next 30 years, the number of Americans age 90 and above is expected to triple, and an NIH-funded research study called 90+ at the University of California Irvine is trying to learn all it can right now from a group of men and women who've already managed to get there. Six years ago, we first reported on their first set of findings. Factors…
Read More

The 90+ Study on 60 Minutes this Sunday

By Commentary, In the News
The 90+ Study, co-led by UCI MIND faculty members Drs. Claudia Kawas and Maria Corrada, will be featured in the show “60 Minutes” this Sunday, November 22 on CBS. The episode will be a follow-up of the study participants who were featured on the show six years ago and an update on research findings since then. Learn more about the feature in the articles below: Lesley Stahl follows up with nonagenarians from landmark study on aging Is there a secret to living well into your 90s?
Read More

Cartographers of the brain

By Carousel Slider, Commentary, In the News
Contributed by UCI News: UCI’s Center for Neural Circuit Mapping is redrawing our understanding of mechanisms underlying several common disorders by Ian Anzlowar, UCI | November 18, 2020 “Our goal is to reveal the molecular changes that occur during the course of Alzheimer’s, impacting learning and memory, and identify a route toward early detection and new drug therapies for the disease,” says Xiangmin Xu, director of UCI’s Center for Neural Circuit Mapping. Steve Zylius / UCI Thanks to Xiangmin Xu and his team at the UCI School of Medicine’s Center for Neural Circuit Mapping, lazy eye, Alzheimer’s and other neurological…
Read More

Deep Sleep Protects Against Alzheimer’s Disease, Growing Evidence Shows

By Commentary
Commentary on NPR article, contributed by Bryce Mander, PhD Numerous studies now show that multiple forms of sleep disturbance increase risk for developing dementia. Emerging work continues to demonstrate that the way in which the brain expresses sleep may be tied to how much Alzheimer’s disease (AD) pathology there is in the brain even prior to AD symptom onset. Both sleep restriction and suppression of high amplitude, low frequency brain waves - called slow waves - during deep sleep increase beta amyloid and tau, the two hallmark pathologies of AD. It is unknown how this occurs, though there is evidence of two potential mechanisms: increased production of AD…
Read More

UCI C2C Registry now live in multiple languages

By Commentary, In the News
UCI Consent-to-Contact (C2C) Registry In 2016, UCI MIND launched a local recruitment registry – the UCI Consent-to-Contact (C2C) Registry – to raise awareness of research participation opportunities at UCI (c2c.uci.edu). We are excited to announce that this fall, the UCI C2C went live in Spanish, Korean, Chinese, and Vietnamese to allow more people to access this online tool. Together with our diverse community, we will improve our understanding of Alzheimer's disease and related dementias in diverse populations and find solutions for people of all backgrounds. To learn more about enrolling in C2C, visit c2c.uci.edu > To read more in our latest newsletter, click here…
Read More

MIND Matters | Quarterly Newsletter | Fall 2020

By Commentary, Community Events, COVID-19, In the News, Participants
Message from the Director   Dear Friends of UCI MIND, As the COVID-19 pandemic continues to impact our lives this fall, the fight to solve Alzheimer’s disease and related dementias (ADRD) must charge forward. This November, the U.S. FDA will convene an advisory committee to assess potential approval of Biogen’s aducanumab, a monoclonal antibody in development for treatment of early AD. We will watch closely as aducanumab could be the first new approved drug for AD since 2005. Regardless of the outcome of the meeting and subsequent FDA decision – anticipated in March 2021 – this represents a milestone for…
Read More

FDA Advisory Panel Recommends Against Approval of Aducanumab for the Treatment of Alzheimer’s Disease

By Commentary, In the News
Many of us listened intently today as the US Food and Drug Administration convened a panel of expert members of an advisory committee to review the submitted materials for potential approval of Biogen’s candidate treatment for early Alzheimer’s disease, aducanumab. The meeting was notable on many levels. Advocates made clear and compelling demonstrations of why new therapies are so desperately needed for this disease. The experts, however, were equally clear that the available data from a still limited number of studies, only one of which was actually positive, do not meet the current standards for drug approval in the United…
Read More

VIDEO: How does heart health impact the brain? with Daniel Nation, PhD

By Commentary, Community Events
ASK THE DOC! UCI MIND Facebook LIVE Video Series This monthly series features short talks and Q&A with experts from the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND), 1 of 32 congressionally designated Alzheimer’s Disease Research Centers in the nation. Join UCI MIND on Facebook (@UCIrvineMIND) to learn about advances in research to improve Alzheimer’s disease diagnosis, treatment, and prevention. How does heart health impact the brain?   About the Speaker: Daniel Nation, PhD is an Associate Professor of Psychological Science in the UCI School of Social Ecology. He earned his PhD in clinical…
Read More

FDA meets today to review aducanumab for the treatment of Alzheimer’s

By Commentary, In the News
The FDA will today convene an advisory committee to review and discuss the application submitted by Biogen Inc. for aducanumab for the treatment of early Alzheimer's disease. Though mixed opinions remain about whether the FDA should approve aducanumab at this time, the submission of a new treatment entity for Alzheimer’s disease is nonetheless good news and an important milestone. It has been nearly two decades since a new drug was approved for Alzheimer’s disease and no approved drug can effectively slow or stop the debilitating progression of this fatal neurodegenerative disease. Regardless of the outcome of this specific submission, we…
Read More

UCI MIND adapts annual fundraiser for Alzheimer’s research with virtual venue

By Carousel Slider, Community Events, In the News
Harriet Harris (second row center) and her family after receiving the UCI MIND Award at the 2019 “A December To Remember” gala event For the first time in the event’s decade-long history, the University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND)’s A December to Remember gala will raise awareness and funds for Alzheimer’s research in a digital setting. While many sectors remain at a standstill due to the pandemic, nonprofits like UCI MIND know that their mission must march forward. The virtual gala event will take place online on Saturday, Dec. 5 from 5:30-7 p.m.,…
Read More